Inverness’ $92.5 Mil. Abbott Rapid Testing Buy Could Return TestPack To U.S.
This article was originally published in The Gray Sheet
Executive Summary
Abbott Labs will retain exclusive distribution rights for the TestPack and Signify test lines in the U.S., while the products' new owner - Inverness Medical Innovations - will take on international distribution responsibilities
You may also be interested in...
Inverness Medical Innovations
$56.5 mil. purchase of Abbott Laboratories' Determine and DainaScreen rapid infectious disease diagnostics will provide the Waltham, Mass. firm with a "viable platform" to "solidify our commitment to the Japanese market," Inverness CEO Ron Zwanziger explains May 31. Inverness previously purchased pregnancy, strep throat, and drugs-of-abuse rapid diagnostic test lines from Abbott for international distribution (1"The Gray Sheet" Oct. 6, 2003, p. 20). Determine/DainaScreen generated roughly $23 mil. for Abbott in 2004...
Inverness Medical Innovations
$56.5 mil. purchase of Abbott Laboratories' Determine and DainaScreen rapid infectious disease diagnostics will provide the Waltham, Mass. firm with a "viable platform" to "solidify our commitment to the Japanese market," Inverness CEO Ron Zwanziger explains May 31. Inverness previously purchased pregnancy, strep throat, and drugs-of-abuse rapid diagnostic test lines from Abbott for international distribution (1"The Gray Sheet" Oct. 6, 2003, p. 20). Determine/DainaScreen generated roughly $23 mil. for Abbott in 2004...
Inverness Will Develop Home-Use Heart Test At Scottish R&D Facility
ITI Life Sciences, a Scottish economic and business development initiative, will provide Inverness Medical Innovations with $57 mil. through 2008 to help identify novel biomarkers for near-patient and home-use cardiovascular disease tests